IOL Chemicals & Pharmaceuticals
IOLCP NSE
IOL Chemicals & Pharmaceuticals
HealthcareNSE: IOLCP BSE: 524164 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹5,944 Cr
Volatility
High Risk
P/E Ratio
33.91
EBITDA
₹290 Cr
Return on Equity
7.65%
Debt to Equity
0.08
Book Value
₹61.27
EPS
₹20.19
52W High
₹219.04
52W Low
₹67.19
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 22.1%
- Promoter holding has increased by 4.80% over last quarter.
Weaknesses
3- Stock is trading at 3.17 times its book value
- The company has delivered a poor sales growth of 3.35% over past five years.
- Company has a low return on equity of 7.74% over last 3 years.
Growth Rate
Revenue Growth
11.36% higher than
3Y
Net Income Growth
36.1% higher than
3Y
Cash Flow Change
19.99% higher than
3Y
ROE
27.71% higher than
3Y
ROCE
21.69% higher than
3Y
EBITDA Margin (Avg.)
16.09% higher than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoAI opinion · based on fundamentals
Risk medium
IOL Chemicals & Pharmaceuticals trades at a market cap of ₹4,300 Cr with a PE of 30.5x and near-zero debt. The company has seen a sharp TTM profit recovery of 44% but carries a weak 5-year sales CAGR of just 3% and a subdued 3-year ROE of 8%.
Bull Case 8
- Company is almost debt-free, providing financial flexibility and lower interest burden
- TTM profit growth of 44% signals a meaningful earnings recovery after years of decline
- Promoter holding increased by 4.86% in the last quarter, indicating insider confidence
- Stock has delivered 53% returns over the past 1 year, reflecting strong momentum
- 10-year compounded profit growth of 19% demonstrates long-term earnings capability
- Healthy dividend payout of 22.1% shows commitment to returning capital to shareholders
- 10-year sales CAGR of 15% indicates the company scaled well over the longer term
- TTM sales growth of 12% suggests demand recovery after a sluggish 3-year period
Bear Case 8
- 5-year compounded profit growth is -20%, indicating a prolonged earnings downcycle
- 5-year sales CAGR of only 3% reflects persistently weak topline growth
- 3-year ROE of just 8% is well below what quality pharma/chemical companies typically deliver
- PE of 30.5x is expensive relative to the low single-digit 3-year sales CAGR of 2%
- 3-year compounded profit growth of only 1% shows the recovery is very recent and unproven
- Last year ROE of 8% and 3-year ROE of 8% show no improvement in capital efficiency
- 5-year stock CAGR of just 2% suggests the market rewarded shareholders poorly over a medium-term horizon
- Dividend yield of 0.7% offers limited income cushion at current valuations
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago Neutral 1
- Minor fire at Minoxidil unit Jun 11
A minor fire at Unit-9B in Barnala on June 9, 2026 has suspended Minoxidil operations for 8–10 days. No injuries or significant property damage reported; all other units operating normally.
TL;DR: IOL Chemicals experienced a contained fire incident at one manufacturing unit with minimal impact—no injuries, no major property damage, and a short 8–10 day suspension limited to a single unit. The event is operationally insignificant given normal functioning across remaining facilities, and the outlook remains unchanged pending restoration completion.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Expenses | 490 | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 |
| Operating Profit | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 93 | 104 |
| OPM % | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% |
| Other Income | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 |
| Interest | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 |
| Depreciation | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 |
| PBT | 62 | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 | 41 | 28 | 71 | 87 |
| Tax % | 25% | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% |
| Net Profit | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 | 30 | 21 | 53 | 64 |
| EPS in Rs | 1.57 | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.7 | 1.08 | 1.16 | 1.02 | 0.7 | 1.81 | 2.2 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,524 |
| Expenses | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,877 | 2,049 | 2,213 |
| Operating Profit | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 270 | 310 |
| OPM % | 2.9% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 12% | 12% |
| Other Income | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 9 | 11 |
| Interest | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 | 14 |
| Depreciation | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 | 82 |
| PBT | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 184 | 226 |
| Tax % | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | 27% | 25% | — |
| Net Profit | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 138 | 168 |
| EPS in Rs | -2.8 | -1.42 | 0.17 | 0.99 | 8.32 | 12.7 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 4.69 | 5.73 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% | 23% | 21% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 | 1,740 |
| Borrowings | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 135 |
| Other Liabilities | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 | 653 |
| Total Liabilities | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 |
| Fixed Assets | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1,170 | 1,181 |
| CWIP | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 | 21 |
| Other Assets | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | 1,168 | 1,289 |
| Total Assets | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,587 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -47 | 18 | 83 | 120 | 273 | 471 | 380 | 91 | 123 | 290 | 179 | 214 |
| Investing | -5 | -27 | -23 | -50 | -63 | -184 | -317 | -121 | -119 | -191 | -154 | -198 |
| Financing | 50 | 9 | -60 | -70 | -197 | -272 | -58 | -2 | -4 | -92 | 46 | -29 |
| Net Cash Flow | -2 | 0 | 1 | -1 | 13 | 15 | 4 | -31 | 0 | 7 | 70 | -13 |
| Free Cash Flow | -53 | -9 | 61 | 71 | 213 | 391 | 272 | -60 | -86 | 18 | -34 | 44 |
| CFO/OP | -413 | 34 | 82 | 105 | 83 | 102 | 88 | 60 | 75 | 144 | 97 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 | 95 |
| Inventory Days | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 | 91 |
| Days Payable | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 | 118 |
| Cash Conversion Cycle | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 | 68 |
| Working Capital Days | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 | 53 |
| ROCE % | -3% | 4% | 12% | 15% | 56% | 68% | 54% | 18% | 14% | 12% | 9% | 11% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view IOL Chemicals & Pharmaceuticals insights
69 extracted metrics + investor summaries across FY06–FY26.
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Sep - Audio recording of 11 September 2026 business update call with investors and analysts made available. 11 Sep - Audio recording of 11 September 2026 business update call with investors and analysts made available.
2
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
2d - Customs authority confirmed Rs 2.06 crore demand, penalty and fine; company will appeal. 2d - Customs authority confirmed Rs 2.06 crore demand, penalty and fine; company will appeal.
5
Disclosure Under Regulation 30 - Participation In 'Saksham Niveshak' Campaign
9 Apr - IOLCP joined IEPFA’s Saksham Niveshak campaign; shareholders to update KYC and claim unpaid dividends by 9 July 2026. 9 Apr - IOLCP joined IEPFA’s Saksham Niveshak campaign; shareholders to update KYC and claim unpaid dividends by 9 July 2026.
Frequently Asked Questions about IOL Chemicals & Pharmaceuticals
What does IOL Chemicals & Pharmaceuticals Ltd do?
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
Where is IOL Chemicals & Pharmaceuticals Ltd (IOLCP) listed?
IOL Chemicals & Pharmaceuticals Ltd trades as IOLCP on the NSE and under code 524164 on the BSE.
Which sector does IOL Chemicals & Pharmaceuticals Ltd belong to?
IOL Chemicals & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd has a market capitalisation of ₹5,944 Cr, which places it in the Mid Cap band.
What is the PE ratio of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd trades at a PE ratio of 33.91, on earnings per share of ₹20.19, against a book value of ₹61.27 per share.
What is the 52-week high and low of IOL Chemicals & Pharmaceuticals Ltd?
Over the last 52 weeks IOL Chemicals & Pharmaceuticals Ltd has traded between ₹67.19 and ₹219.04.
Does IOL Chemicals & Pharmaceuticals Ltd pay dividends?
IOL Chemicals & Pharmaceuticals Ltd has a dividend yield of 0.47%.
What is the Return on Equity (ROE) of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd reported a return on equity of 7.65%. Its debt-to-equity ratio is 0.08.
Company Information
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/IOLCP.md for IOL Chemicals & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.